BTRC and breast cancer: In fact, it has been observed that DNMT1 and E2F3 are candidate targets of miR-152 in HCC, endometrial and breast cancer [44]–[46]; BTRC has been shown to ubiquitinate phosphorylated NFKBIA, targeting it for degradation and thus activating NF-κB [52].